All funds

Longleaf

Mar 2025 → Sep 2026 · Publishes quarterly · 4 funds

Our archive holds 22 letters from Longleaf, behind 32 investment theses and positions in 47 companies. Every quote below is copied verbatim from the letter it came from.

Get an email when this fund publishes its next letter

22
Letters
47
Companies
23
Moves
32
Theses

4 strategies

Longleaf publishes a letter per strategy. Each one has its own page with what it holds, what it bought and what it wrote.

Returns as reported in each strategy’s latest letter, extracted automatically and not verified by us; one share class, in its own currency. Not investment advice. Past performance does not predict future returns.

What they bought and sold · 23 moves

  • September 2026
    “Abbott Labs – This diversified healthcare company is a new holding (owned previously in the 2010s) and is off to a strong start for us.”
    Read the letter
  • September 2026
    “We trimmed our position as the stock approached our value.”
    Read the letter
  • September 2026
    “Thus, the stock at quarter end was a lower weight for us.”
    Read the letter
  • September 2026
    “New investments Abbott Labs and Universal Music Group have great, growing businesses and owner operators on the case.”
    Read the letter
  • September 2026
    “We exited our remaining position in Glanbia after strong execution and a second guidance upgrade drove the share price above our appraisal value.”
    Read the letter
  • “While we had trimmed our position into Q2’s stock price strength, we added later in Q3.”
    Read the letter
  • September 2026
    “Combine the two groups plus our profitable exit of Delivery Hero, and we get underlying results more in the plus mid/high-single-digits range, which makes more sense for the non-AI part of the stock market this year.”
    Read the letter
  • June 2026
    “but we added back to CNX at better prices recently.”
    Read the letter
  • “We trimmed some of our holding when the market was running hotter on Regeneron’s pipeline prospects earlier this year.”
    Read the letter
  • ExitedMenicon
    June 2026
    “We exited our positions in Delivery Hero, as discussed above, and Menicon, which was a smaller position that had approached fair value.”
    Read the letter
  • TrimmedGlanbia
    June 2026
    “the narrowing P/V margin of safety led us to reduce our position during the quarter”
    Read the letter
  • June 2026
    “We added to our investment in the quarter as the stock price pulled back to highly attractive levels.”
    Read the letter
  • June 2026
    “We trimmed our holding earlier in the quarter when the stock was trading well in the wake of the news.”
    Read the letter
  • June 2026
    “we exited our investment as the stock reached our value during the quarter.”
    Read the letter
  • June 2026
    “We also sold the small position in FedEx Freight that we received, as its price was above our appraisal.”
    Read the letter
  • ExitedFedEx Freight
    June 2026
    “We also sold the small position in FedEx Freight that we received, as its price was above our appraisal.”
    Read the letter
  • “We exited our position in Bio- Rad after another disappointing operational quarter led us to conclude that our money would be better invested in the new holding.”
    Read the letter
  • June 2026
    “In our view, the recent share price weakness does not change the long-term opportunity, and we added to our position in the quarter.”
    Read the letter
  • ExitedLouis Hachette
    June 2025
    “We exited two positions, Naver and Louis Hachette.”
    Read the letter
  • June 2025
    “We initiated an investment in Australia-listed Treasury Wine Estates (TWE) during the quarter.”
    Read the letter
  • June 2025
    “We initiated a position in Dutch medical equipment manufacturer Philips during the quarter.”
    Read the letter
  • ExitedNaver
    June 2025
    “As price reached our value, we took the opportunity to exit Naver and recycle capital into more attractive opportunities.”
    Read the letter
  • New positionMedley
    June 2025
    “Medley - Japan's leading online HR platform for medical staff with around 8-10% market share.”
    Read the letter

Companies held · 47

Every company Longleaf has disclosed a position in across our archive, with the letter that last mentioned it.

Theses · 32

Letter archive · 22

Get Longleaf’s next letter the day it lands

We track Longleaf alongside hundreds of other managers, read every letter, and pull out what they bought and sold. Warren AI reads the whole archive for you.

View plans→
Share this fund